Moore Capital Management, LP Cogent Biosciences, Inc. Transaction History

Moore Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.51 - $10.81 $888,177 - $1.28 Million	-118,266 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.99 - $9.14 $21,078 - $32,163	-3,519 Reduced 2.89%	118,266 $995,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.3 $14,553 - $17,307	-1,861 Reduced 1.51%	121,785 $988,000
Q1 2021 May 17, 2021	BUY	$7.47 - $12.34 $79,301 - $131,001	10,616 Added 9.39%	123,646 $1.09 Million
Q4 2020 Feb 16, 2021	BUY	$9.04 - $13.01 $1.02 Million - $1.47 Million	113,030 New	113,030 $1.27 Million

170

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $585M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.